A A A

Eye Therapy News

The Art of Eyes

Thu, 07 Aug 2014 14:23:19 +0000

The eye is an object of great beauty as shown by the Ophthalmologist in their July/August 2014 issue. This month’s issue features a photo essay called The Art of the Eyes and includes examples of the work from a number research labs capturing the complex and beautiful detail of the eye and its cells. The essay includes images […]

Read more...

In memoriam

Tue, 05 Aug 2014 16:02:34 +0000

Dr Yoshiki Sasai (1962 – 2014) It is with great sadness today that we remember and pay tribute to our collaborator Dr Yoshiki Sasai. Yoshiki was a world leading stem cell researcher and Deputy Director of the Riken Center for Developmental Biology in Kobe, Japan. Through his hard work and dedication over many years, Yoshiki […]

Read more...

International Clinical Trials Day: Our Work in Summary

Tue, 20 May 2014 15:03:41 +0000

Introduction Today, 20 May 2014, is International Clinical Trials Day. This landmark day remembers the pioneering work of James Lind a Scottish naval physician who, in the 1700s, conducted the first controlled clinical study that identified that citrus fruit (containing Vitamin C) was effective in treating scurvy. Each year, a number of organisations mark this […]

Read more...

Phase I/II trial to assess safety and efficacy of viral RPE65 gene therapy

Phase I/II trial to assess safety and efficacy of viral RPE65 gene therapy for Leber congenital amaurosis

We began the world's first gene therapy trial in the eye in 2007.

The trial is to test the safety and efficacy of gene therapy using an adeno-associated virus (AAV) to deliver the RPE65 gene to retinal cells in patients who have Leber congenital amaurosis (LCA).

Initial results published in 2008 (Bainbridge et al. NEJM 2011) suggest that the technique is safe and can restore night-vision in some cases.


Further patients have been treated, and the latest arm of the study includes younger patients.

The encouraging results from this trial suggest that gene therapy can be an effective treatment for inherited retinal degeneration, and extensive evidence from laboratory research shows that other diseases that lead to blindness may also be treatable using gene therapy.

Each of these therapies requires the development of a new gene therapy vector and independent safety testing

Pipeline of gene therapy treatments for sight loss

The results of this trial indicate that gene therapy in the eye is safe and can be effective at treating sight loss.

We are developing a pipeline of gene therapy strategies for a range of other conditions that cause sight loss.

Page last modified on 15 jul 14 12:50